DKF 325
Alternative Names: DKF-325Latest Information Update: 28 Apr 2025
At a glance
- Originator Dongkook Pharmaceutical
- Class Anticoagulants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Blood coagulation disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Blood-coagulation-disorders in South Korea
- 09 Mar 2021 Preclinical trials in Blood coagulation disorders in South Korea (unspecified route) before March 2021 (Dongkook pharmaceuticals pipeline, March 2021)